Ovary Adenocarcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: OVR059 MIFTS: 48	Ovary Adenocarcinoma Categories: Cancer diseases, Endocrine diseases, Rare diseases, Reproductive diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Ovary Adenocarcinoma

MalaCards integrated aliases for Ovary Adenocarcinoma:

Name: Ovary Adenocarcinoma ¹¹ ¹⁴

Ovarian Adenocarcinoma ¹¹ ⁵⁸ ²⁸ ⁵ ¹⁶ ⁷¹

Adenocarcinoma of the Ovary ¹¹

Adenocarcinoma of Ovary ⁵⁸

Ovarian Adenoacanthoma ¹¹

Characteristics:

Prevelance:

Adenocarcinoma of Ovary: 1-9/100000 ⁵⁸

Age Of Onset:

Adenocarcinoma of Ovary: Adult ⁵⁸

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Reproductive diseases Endocrine diseases

See all MalaCards categories (disease lists)

ICD10: ³²

Neoplasms

Malignant neoplasms of female genital organs

Malignant neoplasm of ovary

Orphanet: ⁵⁸

Rare gynaecological and obstetric diseases

External Ids:

Disease Ontology ¹¹ DOID:3713

NCIt ⁴⁹ C7700

ICD10 via Orphanet ³² C56

UMLS via Orphanet ⁷² C0948216

Orphanet ⁵⁸ ORPHA213504

EFO ¹⁶ EFO_0006460

UMLS ⁷¹ C0948216

Sources

Summaries for Ovary Adenocarcinoma

Disease Ontology: ¹¹ An ovarian carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary: Ovary Adenocarcinoma, also known as ovarian adenocarcinoma, is related to endometrioid ovary carcinoma and clear cell adenocarcinoma. An important gene associated with Ovary Adenocarcinoma is INHBA (Inhibin Subunit Beta A), and among its related pathways/superpathways are Endometrial cancer and Immune response IL-23 signaling pathway. The drugs Paclitaxel and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include ovary, endothelial and lymph node, and related phenotypes are Increased shRNA abundance (Z-score > 2) and neoplasm

Sources

Related Diseases for Ovary Adenocarcinoma

Diseases related to Ovary Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 516)

#	Related Disease	Score	Top Affiliating Genes
1	endometrioid ovary carcinoma	32.2	TP53 KRAS HRAS H2AC18 ARID1A
2	clear cell adenocarcinoma	31.8	TP53 INHBA ARID1A
3	appendix adenocarcinoma	31.6	TP53 KRAS HRAS CEACAM5
4	mucinous adenocarcinoma	31.5	TP53 KRAS HRAS ERBB2 CEACAM5
5	ovarian cystadenocarcinoma	31.5	TP53 SERPINA3 MIR744 MIR30A MIR196A1 MIR17
6	serous cystadenocarcinoma	31.3	TP53 MIR30A MIR152 KRAS HRAS H2AC18
7	ovarian clear cell adenocarcinoma	31.2	TP53 H2AC18 ESS2 ARID1A
8	ovarian cancer	31.1	TP53 MIR30A MIR29C MIR196A1 MIR17 KRAS
9	papillary adenocarcinoma	31.1	TP53 MIR30A KRAS HRAS ERBB2 CEACAM5
10	adenoid squamous cell carcinoma	31.1	TP53 CEACAM5
11	adenofibroma	31.0	TP53 KRAS ARID1A
12	cystadenocarcinoma	31.0	TP53 SERPINA3 MIR30A KRAS CEACAM5 BRCA1
13	papillary serous adenocarcinoma	30.9	TP53 MIR30A KRAS HRAS ESS2 ERBB2
14	pseudomyxoma peritonei	30.8	TP53 KRAS CEACAM5
15	fallopian tube carcinoma	30.8	TP53 ERBB2 BRCA1
16	endometrial cancer	30.7	TP53 MIR30A MIR152 KRAS HRAS H2AC18
17	adenocarcinoma	30.6	TP53 KRAS HRAS ERBB2 CEACAM5 BAX
18	cystadenoma	30.6	SERPINA3 CEACAM5 BRCA1
19	carcinosarcoma	30.6	TP53 KRAS HRAS ERBB2
20	endometrial adenocarcinoma	30.6	TP53 SERPINA3 MIR152 KRAS
21	mucinous cystadenocarcinoma	30.5	SERPINA3 KRAS HRAS CEACAM5
22	ovarian serous carcinoma	30.5	TP53 HRAS H2AC18 BRCA1
23	teratoma	30.5	TP53 KRAS ERBB2 CEACAM5
24	pilocytic astrocytoma	30.5	TP53 SERPINA3 KRAS HRAS
25	rectal benign neoplasm	30.5	TP53 MIR17 KRAS HRAS CEACAM5
26	myoma	30.5	TP53 KRAS CEACAM5
27	small-cell carcinoma of the ovary of hypercalcemic type	30.5	TP53 ARID1A
28	endometrial hyperplasia	30.4	TP53 KRAS ARID1A
29	meningioma, familial	30.4	TP53 SERPINA3 HRAS H2AC18 ERBB2
30	female reproductive endometrioid cancer	30.4	TP53 KRAS HRAS ERBB2 BRCA1 ARID1A
31	colonic benign neoplasm	30.4	TP53 SERPINA3 KRAS HRAS H2AC18 ERBB2
32	colorectal adenocarcinoma	30.4	TP53 MIR17 KRAS HRAS H2AC18 ERBB2
33	rectum cancer	30.4	TP53 MIR30A MIR17 KRAS HRAS H2AC18
34	lymphatic system disease	30.4	TP53 SERPINA3 MIR30A MIR29C MIR196A1 MIR17
35	colon adenocarcinoma	30.4	TP53 KRAS HRAS CEACAM5 BAX ARID1A
36	ovarian clear cell carcinoma	30.3	TP53 KRAS HRAS H2AC18 ESS2 BRCA1
37	vaginal cancer	30.3	TP53 HRAS BRCA1
38	ovarian mucinous cystadenocarcinoma	30.3	SERPINA3 CEACAM5
39	adenocarcinoma in situ	30.3	TP53 KRAS HRAS CEACAM5
40	bladder cancer	30.3	TP53 MIR29C MIR17 KRAS HRAS H2AC18
41	squamous cell carcinoma	30.2	TP53 KRAS HRAS ERBB2 CEACAM5
42	skin melanoma	30.2	TP53 KRAS HRAS H2AC18 ERBB2
43	cervical squamous cell carcinoma	30.2	TP53 KRAS CEACAM5 ARID1A
44	endocervical adenocarcinoma	30.2	TP53 HRAS ERBB2 CEACAM5 ARID1A
45	gallbladder disease	30.2	TP53 SERPINA3 MIR30A MIR29C MIR196A1 MIR17
46	ovarian disease	30.2	TP53 MIR30A MIR17 H2AC18 ERBB2 BRCA1
47	gastrointestinal stromal tumor	30.1	TP53 SERPINA3 KRAS HRAS H2AC18 ERBB2
48	ovarian carcinosarcoma	30.1	TP53 KRAS HRAS H2AC18 ERBB2 BRCA1
49	thyroid gland cancer	30.1	TP53 MIR17 KRAS HRAS H2AC18 ERBB2
50	rhabdomyosarcoma	30.0	TP53 MIR29C KRAS HRAS ERBB2 CEACAM5

Graphical network of the top 20 diseases related to Ovary Adenocarcinoma:

Sources

Symptoms & Phenotypes for Ovary Adenocarcinoma

GenomeRNAi Phenotypes related to Ovary Adenocarcinoma according to GeneCards Suite gene sharing:

²⁵ (show all 22)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Increased shRNA abundance (Z-score > 2)	GR00366-A-120	9.72	KRAS
2	Increased shRNA abundance (Z-score > 2)	GR00366-A-137	9.72	BRCA1
3	Increased shRNA abundance (Z-score > 2)	GR00366-A-139	9.72	BRCA1
4	Increased shRNA abundance (Z-score > 2)	GR00366-A-161	9.72	ERBB2
5	Increased shRNA abundance (Z-score > 2)	GR00366-A-168	9.72	ARID1A BRCA1 ERBB2
6	Increased shRNA abundance (Z-score > 2)	GR00366-A-176	9.72	ARID1A
7	Increased shRNA abundance (Z-score > 2)	GR00366-A-186	9.72	ARID1A
8	Increased shRNA abundance (Z-score > 2)	GR00366-A-190	9.72	ARID1A
9	Increased shRNA abundance (Z-score > 2)	GR00366-A-204	9.72	BRCA1
10	Increased shRNA abundance (Z-score > 2)	GR00366-A-207	9.72	ERBB2
11	Increased shRNA abundance (Z-score > 2)	GR00366-A-211	9.72	BRCA1
12	Increased shRNA abundance (Z-score > 2)	GR00366-A-213	9.72	ARID1A
13	Increased shRNA abundance (Z-score > 2)	GR00366-A-22	9.72	KRAS
14	Increased shRNA abundance (Z-score > 2)	GR00366-A-32	9.72	ERBB2
15	Increased shRNA abundance (Z-score > 2)	GR00366-A-43	9.72	ARID1A
16	Increased shRNA abundance (Z-score > 2)	GR00366-A-60	9.72	ERBB2
17	Increased shRNA abundance (Z-score > 2)	GR00366-A-63	9.72	ERBB2 KRAS
18	Increased shRNA abundance (Z-score > 2)	GR00366-A-73	9.72	ARID1A
19	Increased shRNA abundance (Z-score > 2)	GR00366-A-82	9.72	H2AC18
20	Increased shRNA abundance (Z-score > 2)	GR00366-A-85	9.72	ERBB2
21	Increased shRNA abundance (Z-score > 2)	GR00366-A-87	9.72	ERBB2
22	Increased shRNA abundance (Z-score > 2)	GR00366-A-99	9.72	H2AC18

MGI Mouse Phenotypes related to Ovary Adenocarcinoma:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	neoplasm	MP:0002006	9.76	ARID1A BAX BRCA1 CEACAM5 ERBB2 HRAS
2	muscle	MP:0005369	9.61	ARID1A BAX BRCA1 CEACAM5 ERBB2 HRAS
3	skeleton	MP:0005390	9.32	ARID1A BAX BRCA1 C1RL ERBB2 HRAS

Sources

Drugs & Therapeutics for Ovary Adenocarcinoma

Drugs for Ovary Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 60)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Paclitaxel

Approved, Vet_approved

Phase 3

33069-62-4

36314

Carboplatin

Approved

Phase 3

41575-94-4

10339178 38904

Letrozole

Approved, Investigational

Phase 3

112809-51-5

3902

Progesterone

Approved, Vet_approved

Phase 3

57-83-0

5994

Albumin-Bound Paclitaxel

Phase 3

Antimitotic Agents

Phase 3

Tubulin Modulators

Phase 3

Estrogens

Phase 3

Estrogen Receptor Antagonists

Phase 3

Estrogen Antagonists

Phase 3

Hormones

Phase 3

Hormone Antagonists

Phase 3

Aromatase Inhibitors

Phase 3

Bevacizumab

Approved, Investigational

Phase 2

216974-75-3

135329020

Nintedanib

Approved

Phase 2

656247-17-5

135423438 9809715

Levoleucovorin

Approved, Experimental, Investigational

Phase 1, Phase 2

68538-85-2, 58-05-9, 73951-54-9

149436 6006

Nivolumab

Approved

Phase 2

946414-94-4

Ipilimumab

Approved

Phase 2

477202-00-9

Fludarabine

Approved

Phase 1, Phase 2

75607-67-9, 21679-14-1

30751 657237

Niraparib

Approved, Investigational

Phase 2

1038915-60-4

24958200

Pembrolizumab

Approved

Phase 2

1374853-91-4

254741536

Aldesleukin

Approved

Phase 2

110942-02-4

Sargramostim

Approved, Investigational

Phase 2

123774-72-1

Folic acid

Approved, Nutraceutical, Vet_approved

Phase 1, Phase 2

59-30-3

6037

Spartalizumab

Investigational

Phase 2

1935694-88-4

Exatecan

Investigational

Phase 1, Phase 2

171335-80-1

18546929 151115

Oregovomab

Investigational

Phase 2

213327-37-8

Molgramostim

Investigational

Phase 2

99283-10-0

Angiogenesis Inhibitors

Phase 2

Immunoglobulins, Intravenous

Phase 2

Immunoglobulin G

Phase 2

Endothelial Growth Factors

Phase 2

Mitogens

Phase 2

Protein Kinase Inhibitors

Phase 2

Immune Checkpoint Inhibitors

Phase 2

Folate

Phase 1, Phase 2

Vitamin B9

Phase 1, Phase 2

Vitamin B Complex

Phase 1, Phase 2

Interleukin-2

Phase 1, Phase 2

Poly(ADP-ribose) Polymerase Inhibitors

Phase 2

Immunoglobulins

Phase 2

Antibodies

Phase 2

Antineoplastic Agents, Immunological

Phase 2

Antibodies, Monoclonal

Phase 2

Immunologic Factors

Phase 2

Vaccines

Phase 2

Antiviral Agents

Phase 2

Anti-Infective Agents

Phase 2

Anti-Retroviral Agents

Phase 2

Adjuvants, Immunologic

Phase 2

Interventional clinical trials:

(show all 19)

#	Name	Status	NCT ID	Phase	Drugs
1	Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer: a Randomized Phase III Trial (LEPRE Trial)	Recruiting	NCT05601700	Phase 3	Letrozole tablets;carboplatin AUC 5 and paclitaxel 175 mg/m2
2	OVax®: A Feasibility Study Using a DNP-Modified Autologous Ovarian Tumor Cell Vaccine as Therapy in Ovarian Cancer Patients After Relapse:	Unknown status	NCT00660101	Phase 1, Phase 2
3	Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.	Completed	NCT03365791	Phase 2
4	A Randomized Phase II Induction Discontinuation Trial of Emactuzumab Following Paclitaxel and Bevacizumab in Patients With Platinum-Resistant, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Completed	NCT02923739	Phase 2	Paclitaxel
5	Randomized Double Blind Placebo-controlled Phase II Trial of Vargatef® (Nintedanib) in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Adenocarcinoma of the Ovary, the Fallopian Tube or Serous Adenocarcinoma of the Peritoneum	Completed	NCT01583322	Phase 2	vargatef;placebo
6	Dose Escalation and Expansion Clinical Study to Evaluate the Safety and Efficacy of ELU001 in Subjects Who Have Advanced, Recurrent or Refractory FRα Overexpressing Tumors	Recruiting	NCT05001282	Phase 1, Phase 2	ELU001
7	DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors	Recruiting	NCT02834013	Phase 2
8	A Phase 1/2 Single Arm Open-Label Clinical Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer	Recruiting	NCT05451849	Phase 1, Phase 2	Fludarabine;Cyclophosphamide
9	A Phase 1/2 Open-Label, Multicenter, Dose Escalation and Expansion Study of AVB-001, an Intraperitoneally Administered, Cell-Generated, Human IL-2 Immunotherapy in Patients With Platinum-Resistant, High-Grade, Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube	Recruiting	NCT05538624	Phase 1, Phase 2	AVB-001 (Dose Escalation Phase);AVB-001 (Dose Expansion Phase)
10	Phase 2, Single Arm Clinical Trial to Evaluate the Safety and Activity of Oregovomab and Niraparib as a Combinatorial Immune Priming Strategy in Subjects With Platinum Sensitive Recurrent Ovarian Cancer	Recruiting	NCT05335993	Phase 2	Niraparib
11	Randomized Phase II Trial Evaluating Compliance With Monitoring Conducted Either by a Hospital-based Physician in Person or by a Nurse in Remote Monitoring	Not yet recruiting	NCT05500391	Phase 2
12	Phase 2 Randomized Open-label Multicenter Study of Combination of ONC-392 and Pembrolizumab for the Treatment of Patients With Platinum Resistant Ovarian Cancer (PROC)	Not yet recruiting	NCT05446298	Phase 2	ONC-392;Pembrolizumab
13	Vaccine Therapy With Tumor Specific p53 Peptides in Adult Patients With Low Burden Adenocarcinoma of the Ovary	Terminated	NCT00001827	Phase 2
14	Phase I Study of Cisplatin Hyperthermic Intraperitoneal Chemotherapy Dose Escalation After Surgery in Patients With Unresectable Stage IIIC Ovarian, Tube or Peritoneal Primary Adenocarcinoma Previously Treated by Chemotherapy and Completed by Bevacizumab for 15 Months	Completed	NCT02217956	Phase 1	Cisplatin;Bevacizumab
15	A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (Anti-FRα Antibody-drug Conjugate) in Adult Patients With Recurrent Endometrial Cancer and Recurrent, High-Grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers	Recruiting	NCT05527184	Phase 1	IMGN151
16	A Phase 1 Study of Intraperitoneal MCY-M11 Therapy for Women With Platinum Resistant High Grade Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube, or Subjects With Peritoneal Mesothelioma With Recurrence After Prior Chemotherapy	Terminated	NCT03608618	Phase 1	Cyclophosphamide
17	The CINSARC Genomic Signature as a Predictor of Resectability of High Grade Serous Ovarian Adenocarcinomas	Unknown status	NCT04248231
18	A Prospective, Longitudinal Study of YKL-40 in Patients With FIGO Stage III or IV Invasive Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Undergoing Primary Chemotherapy	Terminated	NCT00899093
19	The Effects of Moderate Exercise on Distress, Quality of Life, and Biomarkers of Angiogenesis and Chronic Stress in Ovarian Cancer Survivors - A Randomized Controlled Trial	Terminated	NCT03641287

Search NIH Clinical Center for Ovary Adenocarcinoma

Sources

Genetic Tests for Ovary Adenocarcinoma

Genetic tests related to Ovary Adenocarcinoma:

#	Genetic test	Affiliating Genes
1	Ovarian Adenocarcinoma ²⁸

Sources

Anatomical Context for Ovary Adenocarcinoma

Organs/tissues related to Ovary Adenocarcinoma:

MalaCards : Ovary, Endothelial, Lymph Node, Breast, Bone Marrow, Cervix, T Cells

Sources

Publications for Ovary Adenocarcinoma

Articles related to Ovary Adenocarcinoma:

(show top 50) (show all 1491)

#	Title	Authors	PMID	Year
1	Prediction of cancer driver mutations in protein kinases. ⁵	Torkamani A...Schork NJ	18339846	2008
2	Mixed neuroendocrine/Non-neuroendocrine neoplasm (MiNEN) of gastrointestinal lineage arising in an ovarian mature cystic teratoma. ⁶²	Dasaraju S...Khalifa MA	36388757	2022
3	Analysis of bioactive compounds using LC-ESI-MS/MS, cytotoxic, antimicrobial effects, and enzyme activities from Cyclotrichium origanifolium. ⁶²	Aktepe N...Jahan I	36366959	2022
4	Green Biosynthesis of Silver Nanoparticles Using Annona glabra and Annona squamosa Extracts with Antimicrobial, Anticancer, Apoptosis Potentials, Assisted by In Silico Modeling, and Metabolic Profiling. ⁶²	Mokhtar FA...Ibrahim RM	36355526	2022
5	Molecular analysis for refractory rare cancers: Sequencing battle continues - learnings for the MOSCATO-01 study. ⁶²	Debien V...Verlingue L	36460264	2022
6	Involvement of Bid in the crosstalk between ferroptotic agent-induced ER stress and TRAIL-induced apoptosis. ⁶²	Kim JH...Lee YJ	35994698	2022
7	Suppression of the Antioxidant System and PI3K/Akt/mTOR Signaling Pathway in Cisplatin-Resistant Cancer Cells by Quercetin. ⁶²	Hasan AAS...Shtil AA	36322312	2022
8	Ferrocifen stealth LNCs and conventional chemotherapy: A promising combination against multidrug-resistant ovarian adenocarcinoma. ⁶²	Idlas P...Passirani C	36089209	2022
9	Surgical management of a solitary metastatic ovarian adenocarcinoma with colonic origin presenting as gigantic bilateral ovarian masses. ⁶²	Ahmadi Tafti SM...Hadizadeh A	36110333	2022
10	Neuroendocrine Tumor of the Fallopian Tube and Serous Adenocarcinoma of the Ovary: Multicentric Primary Tumors. ⁶²	Hyriavenko N...Romaniuk A	36178284	2022
11	In Vivo Effects of Conditioned Medium from Human Uterine Cervical Stem Cells in an Ovarian Cancer Xenograft Mouse Model. ⁶²	Sendon-Lago J...Schneider J	35985689	2022
12	Anti-Tumoral Effect of Chemerin on Ovarian Cancer Cell Lines Mediated by Activation of Interferon Alpha Response. ⁶²	Schmitt M...Treeck O	36077645	2022
13	Ovarian Adenocarcinoma With Leptomeningeal Metastases. ⁶²	Bayas A...Swerdloff MA	36059325	2022
14	Suppression of PI3K/Akt/mTOR Signaling Pathway and Antioxidant System and Reversal of Cancer Cells Resistance to Cisplatin under the Effect of Curcumin. ⁶²	Kalinina EV...Shtil AA	35854021	2022
15	Mesenteric Panniculitis Appears as Metastatic Disease on 18F-FDG-PET/CT Scan. ⁶²	Ekmekcioglu O...Sonmezoglu K	35771041	2022
16	The photodynamic reaction with IR-775 cyanine combined with 2-methoxyestradiol in ovarian (SKOV-3) and human breast adenocarcinoma (MDA MB-231) cell lines. ⁶²	Waszkiewicz M...Saczko J	35182779	2022
17	ALCAM/CD166 Is Involved in the Binding and Uptake of Cancer-Derived Extracellular Vesicles. ⁶²	Cardenes B...Cabanas C	35628559	2022
18	Retroviral association with ovarian adenocarcinoma in laying hens. ⁶²	Ramoutar VV...Stewart MC	34807789	2022
19	Ovarian adenocarcinoma in 14-year-old girl. ⁶²	Drosdzol-Cop A...Stojko R	35419802	2022
20	Primary ovarian adenocarcinoma presenting with rubeotic glaucoma and vitritis: A case report. ⁶²	Abu-Yaghi N...Abu Shahin N	35425610	2022
21	Rare association of the ovarian adenocarcinoma with pregnancy: A case report. ⁶²	Bouab M...Karkouri M	35198187	2022
22	Amphiphilic Cell-Penetrating Peptides Containing Natural and Unnatural Amino Acids as Drug Delivery Agents. ⁶²	Salehi D...Parang K	35406720	2022
23	New flavone, and cytotoxicity activity of Rauia resinosa ethanolic extract and constituents. ⁶²	Sousa JAC...Brandao GC	35142584	2022
24	Patient-Derived Ovarian Cancer Spheroids Rely on PI3K-AKT Signaling Addiction for Cancer Stemness and Chemoresistance. ⁶²	Parashar D...Chaluvally-Raghavan P	35205706	2022
25	Identification of best housekeeping genes for the normalization of RT-qPCR in human cell lines. ⁶²	da Conceicao Braga L...Silva LM	34861601	2022
26	StarD13 negatively regulates invadopodia formation and invasion in high-grade serous (HGS) ovarian adenocarcinoma cells by inhibiting Cdc42. ⁶²	Abdellatef S...El-Sibai M	34958986	2022
27	Gene co-expression network analysis revealed novel biomarkers for ovarian cancer. ⁶²	Kasavi C	36338962	2022
28	A monoclonal antibody against annexin A2 targets stem and progenitor cell fractions in tumors. ⁶²	Kalra RS...Bapat SA	34715620	2022
29	[(WR)8WKβA]-Doxorubicin Conjugate: A Delivery System to Overcome Multi-Drug Resistance against Doxorubicin. ⁶²	Zoghebi K...Parang K	35053417	2022
30	Mesonephric-like Adenocarcinoma of the Ovary: Clinicopathological and Molecular Characteristics. ⁶²	Koh HH...Kim HS	35204416	2022
31	Phytochemical, Cytotoxic, and Antimicrobial Evaluation of Tribulus terrestris L., Typha domingensis Pers., and Ricinus communis L.: Scientific Evidences for Folkloric Uses. ⁶²	Khalid A...Abdalla AN	35126602	2022
32	Reactive Hemophagocytic Lymphohistiocytosis Secondary to Ovarian Adenocarcinoma: A Rare Case Report. ⁶²	Li XY...Geng YL	36097636	2022
33	Incidental Finding of Endometrioid Adenocarcinoma of the Ovary on 131I Whole-Body Scan. ⁶²	Mohd Rohani MF...Amir Hassan SZ	34028418	2022
34	A 47-year-old man with rare serous cyst adenocarcinoma of the testis. ⁶²	Pourvali-Souraki Z...Alizadeh-Navaei R	35381807	2022
35	Fatal pulmonary tumour thrombotic microangiopathy in patient with ovarian adenocarcinoma: review and a case report. ⁶²	Neverauskaite-Piliponiene G...Ereminiene E	34986798	2022
36	Intracellular dynamics of the Sigma-1 receptor observed with super-resolution imaging microscopy. ⁶²	Kopanchuk S...Rinken A	35584184	2022
37	Mesonephric-like adenocarcinoma of the ovary in an elderly woman: A case report and a review of the literature. ⁶²	Ujita M...Konishi I	34580958	2021
38	Design and application of hybrid cyclic-linear peptide-doxorubicin conjugates as a strategy to overcome doxorubicin resistance and toxicity. ⁶²	Mozaffari S...Parang K	34537446	2021
39	Association of body composition with toxicity to first-line chemotherapy and three-year survival in women with ovarian adenocarcinoma. ⁶²	Bruno KA...Chaves GV	34634224	2021
40	Cure of Mice with Advanced Ovarian Adenocarcinoma CaO1 by the Serum Blood Proteins. ⁶²	Donenko FV...Lebedin YS	34855090	2021
41	Loss of hexokinase 1 sensitizes ovarian cancer to high-dose metformin. ⁶²	Simcikova D...Heneberg P	34895333	2021
42	miR-152-mediated MKK7 downregulation is attenuated by MYCNOS in ovarian adenocarcinoma. ⁶²	Zhang G...Yu J	34733360	2021
43	Spatial transcriptomics at subspot resolution with BayesSpace. ⁶²	Zhao E...Gottardo R	34083791	2021
44	Platinum resistance in gynecologic malignancies: Response, disease free and overall survival are predicted by biochemical signature: A metabolomic analysis. ⁶²	D'Amora P...Nagourney RA	34446269	2021
45	Development and identification of a prognostic nomogram model for patients with mixed cell adenocarcinoma of the ovary. ⁶²	Wu H...Zhang S	34674727	2021
46	Induction of apoptosis on ovarian adenocarcinoma cells, A2780 by tricyclohexylphosphanegold (I) mercaptobenzoate derivatives via intrinsic and extrinsic pathways. ⁶²	Ang KP...Hamid RA	34476610	2021
47	Hybrid Cyclic-Linear Cell-Penetrating Peptides Containing Alternative Positively Charged and Hydrophobic Residues as Molecular Transporters. ⁶²	Khayyatnejad Shoushtari S...Parang K	34491768	2021
48	Long-term experience with percutaneous biopsies of pelvic lesions using CT guidance. ⁶²	Hoffmann P...Dvorak P	34918561	2021
49	A case of Endometrioid endometrial adenocarcinoma with synchronous low-grade Appendiceal mucinous neoplasm and Pseudomyxoma peritonei. ⁶²	Raje S...Rao G	33605928	2021
50	Preclinical evaluation of anti-VEGFR2 monoclonal antibody ramucirumab labelled with zirconium-89 for tumour imaging. ⁶²	Novy Z...Trejtnar F	33818828	2021

Sources

Genes for Ovary Adenocarcinoma

Genes related to Ovary Adenocarcinoma (1 elite genes):

(show top 50) (show all 52)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	INHBA	Inhibin Subunit Beta A	Protein Coding	354	Causative germline mutation ⁵⁸ DISEASES inferred ¹⁴	24302632
2	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	31.49	Likely pathogenic ⁵ DISEASES inferred ¹⁴	18339846
3	C1RL	Complement C1r Subcomponent Like	Protein Coding	10.16	DISEASES inferred ¹⁴ GeneCards inferred via : Expressions (show sections)
4	BAX	BCL2 Associated X, Apoptosis Regulator	Protein Coding	10	DISEASES inferred ¹⁴ GeneCards inferred via : Expressions (show sections)
5	H2AC18	H2A Clustered Histone 18	Protein Coding	8.03	DISEASES inferred ¹⁴ ¹⁴
6	SERPINA3	Serpin Family A Member 3	Protein Coding	7.79	DISEASES inferred ¹⁴ ¹⁴
7	MIR152	MicroRNA 152	RNA Gene	7.58	DISEASES inferred ¹⁴ ¹⁴
8	MIR30A	MicroRNA 30a	RNA Gene	7.28	DISEASES inferred ¹⁴ ¹⁴
9	TP53	Tumor Protein P53	Protein Coding	7.25	DISEASES inferred ¹⁴
10	MIR17	MicroRNA 17	RNA Gene	7.14	DISEASES inferred ¹⁴ ¹⁴
11	MIR29C	MicroRNA 29c	RNA Gene	6.92	DISEASES inferred ¹⁴ ¹⁴
12	MIR196A1	MicroRNA 196a-1	RNA Gene	6.88	DISEASES inferred ¹⁴ ¹⁴
13	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	6.81	DISEASES inferred ¹⁴
14	ARID1A	AT-Rich Interaction Domain 1A	Protein Coding	6.8	DISEASES inferred ¹⁴
15	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	6.79	DISEASES inferred ¹⁴
16	CEACAM5	CEA Cell Adhesion Molecule 5	Protein Coding	6.72	DISEASES inferred ¹⁴
17	ESS2	Ess-2 Splicing Factor Homolog	Protein Coding	6.71	DISEASES inferred ¹⁴
18	BRCA1	BRCA1 DNA Repair Associated	Protein Coding	6.71	DISEASES inferred ¹⁴
19	MIR101-1	MicroRNA 101-1	RNA Gene	6.7	DISEASES inferred ¹⁴ ¹⁴
20	MIR744	MicroRNA 744	RNA Gene	6.55	DISEASES inferred ¹⁴ ¹⁴
21	KRT7	Keratin 7	Protein Coding	6.48	DISEASES inferred ¹⁴
22	PTEN	Phosphatase And Tensin Homolog	Protein Coding	6.48	DISEASES inferred ¹⁴
23	PIK3CA	Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha	Protein Coding	6.46	DISEASES inferred ¹⁴
24	OVAAL	Ovarian Adenocarcinoma Amplified Long Non-Coding RNA	RNA Gene	6.43	DISEASES inferred ¹⁴
25	BRCA2	BRCA2 DNA Repair Associated	Protein Coding	6.43	DISEASES inferred ¹⁴
26	CTNNB1	Catenin Beta 1	Protein Coding	6.4	DISEASES inferred ¹⁴
27	MIR22	MicroRNA 22	RNA Gene	6.39	DISEASES inferred ¹⁴ ¹⁴
28	AKT1	AKT Serine/Threonine Kinase 1	Protein Coding	6.3	DISEASES inferred ¹⁴
29	U2AF1	U2 Small Nuclear RNA Auxiliary Factor 1	Protein Coding	6.24	DISEASES inferred ¹⁴ ¹⁴
30	ICOSLG	Inducible T Cell Costimulator Ligand	Protein Coding	6.23	DISEASES inferred ¹⁴ ¹⁴
31	PAX8	Paired Box 8	Protein Coding	6.23	DISEASES inferred ¹⁴
32	EGFR	Epidermal Growth Factor Receptor	Protein Coding	6.2	DISEASES inferred ¹⁴
33	GNAS	GNAS Complex Locus	Protein Coding	6.16	DISEASES inferred ¹⁴
34	MIR483	MicroRNA 483	RNA Gene	6.13	DISEASES inferred ¹⁴ ¹⁴
35	SLC25A16	Solute Carrier Family 25 Member 16	Protein Coding	6.12	DISEASES inferred ¹⁴
36	ESR1	Estrogen Receptor 1	Protein Coding	6.11	DISEASES inferred ¹⁴
37	MYC	MYC Proto-Oncogene, BHLH Transcription Factor	Protein Coding	6.1	DISEASES inferred ¹⁴
38	GAPDH	Glyceraldehyde-3-Phosphate Dehydrogenase	Protein Coding	6.09	DISEASES inferred ¹⁴
39	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	6.08	DISEASES inferred ¹⁴
40	MUC16	Mucin 16, Cell Surface Associated	Protein Coding	6.05	DISEASES inferred ¹⁴
41	CDH1	Cadherin 1	Protein Coding	6.03	DISEASES inferred ¹⁴
42	WT1	WT1 Transcription Factor	Protein Coding	6.02	DISEASES inferred ¹⁴
43	ACTB	Actin Beta	Protein Coding	5.92	DISEASES inferred ¹⁴
44	MUC1	Mucin 1, Cell Surface Associated	Protein Coding	5.89	DISEASES inferred ¹⁴
45	ERCC6	ERCC Excision Repair 6, Chromatin Remodeling Factor	Protein Coding	5.84	DISEASES inferred ¹⁴ ¹⁴
46	PGR	Progesterone Receptor	Protein Coding	5.81	DISEASES inferred ¹⁴
47	CDX2	Caudal Type Homeobox 2	Protein Coding	5.8	DISEASES inferred ¹⁴
48	VEGFA	Vascular Endothelial Growth Factor A	Protein Coding	5.77	DISEASES inferred ¹⁴
49	CD8A	CD8a Molecule	Protein Coding	5.75	DISEASES inferred ¹⁴
50	MLH1	MutL Homolog 1	Protein Coding	5.68	DISEASES inferred ¹⁴

Sources

Variations for Ovary Adenocarcinoma

ClinVar genetic disease variations for Ovary Adenocarcinoma:

⁵

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	ERBB2	NM_004448.4(ERBB2):c.2570A>G (p.Asn857Ser)	SNV	Likely Pathogenic	13880	rs28933370	GRCh37: 17:37881378-37881378 GRCh38: 17:39725125-39725125

Copy number variations for Ovary Adenocarcinoma from CNVD:

⁶

#	CNVD ID	Chromosome	Start	End	Type	Gene Symbol	CNVD Disease
1	118124	17	7571720	7590868	Mutation	TP53	Ovarian adenocarcinomas

Sources

Expression for Ovary Adenocarcinoma

Search GEO for disease gene expression data for Ovary Adenocarcinoma.

Sources

Pathways for Ovary Adenocarcinoma

Pathways related to Ovary Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 25)

#	Super pathways	Score	Top Affiliating Genes
1	Endometrial cancer ⁷⁴ Show member pathways Chromosomal and microsatellite instability in colorectal cancer ⁷⁴ Melanoma ⁷⁴ Non-small cell lung cancer ⁷⁴ Pancreatic adenocarcinoma pathway ⁷⁴ Signal transduction PTEN pathway ²²	12.55	TP53 KRAS HRAS ERBB2 BAX
2	Immune response IL-23 signaling pathway ²² Show member pathways Angiopoietin receptor Tie2-mediated signaling ⁶¹ Angiopoietin-TIE2 Signaling ⁶⁴ Development Angiopoietin - Tie2 signaling ²² Development PDGF signaling via STATs and NF-kB ²² IL23-mediated signaling events ⁶¹ Immune response IL-10 signaling pathway ²² RAC1/PAK1/p38/MMP2 pathway ⁷⁴	12.41	TP53 KRAS HRAS ERBB2 BAX
3	Development EGFR signaling pathway ²² Show member pathways Development ERBB-family signaling ²² EGF Pathway ⁶⁴ EGFR Signaling Pathway ⁶⁷ ErbB receptor signaling network ⁶¹	12.35	ERBB2 HRAS KRAS TP53
4	Hepatocyte growth factor receptor signaling ⁷⁴ Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²² Apoptosis and survival NGF signaling pathway ²² Apoptosis and survival Role of CDK5 in neuronal death and survival ²² Development HGF signaling pathway ²² Development Neurotrophin family signaling ²² Drug-mediated inhibition of MET activation ⁶⁶ MET activates PTPN11 ⁶⁶ MET activates STAT3 ⁶⁶ PLC-gamma1 signalling ⁶⁶ Trk receptor signaling mediated by PI3K and PLC-gamma ⁶¹ TRKA activation by NGF ⁶⁶	12.34	TP53 HRAS ERBB2 BAX
5	NF-kappaB Pathway ⁷⁰ Show member pathways Akt Pathway ⁷⁰ Apoptosis Pathway ⁷⁰	12.18	TP53 KRAS HRAS ERBB2 BAX
6	Breast cancer pathway ⁷⁴ Show member pathways Embryonic stem cell pluripotency pathways ⁷⁴	12.17	TP53 KRAS HRAS ERBB2 BRCA1 BAX
7	NGF Pathway ⁶⁴ Show member pathways MAPK and NFkB signaling pathways inhibited by Yersinia YopJ ⁷⁴ TRKA Signaling ⁶⁴	12.02	TP53 KRAS HRAS BAX
8	MAPK Signaling: Mitogens ⁶⁵ Show member pathways Akt Signaling Pathway ⁶⁵	12.02	TP53 KRAS HRAS ERBB2 BAX
9	Integrated breast cancer pathway ⁷⁴	11.97	BAX BRCA1 KRAS TP53
10	DNA IR-double strand breaks and cellular response via ATM ⁷⁴ Show member pathways ATM pathway ⁶¹ DNA damage_DNA-damage-induced responses ²²	11.79	TP53 BRCA1 BAX
11	VEGF Pathway (Tocris) ⁷⁰ Show member pathways Sorafenib Pharmacodynamics ⁶⁰	11.67	KRAS HRAS BAX
12	mTOR Pathway ⁷⁰ Show member pathways TGF-beta Pathway ⁷⁰	11.67	TP53 KRAS HRAS
13	MAPK Signaling: Oxidative Stress ⁶⁵	11.66	TP53 KRAS BAX
14	Burn wound healing ⁷⁴	11.63	TP53 INHBA BAX
15	miRNAs involved in DNA damage response ⁷⁴	11.56	TP53 MIR29C MIR17
16	Head and neck squamous cell carcinoma ⁷⁴	11.49	ERBB2 HRAS KRAS TP53
17	Agrin Interactions at Neuromuscular Junction ⁶⁴	11.48	KRAS HRAS ERBB2
18	Hepatitis C and hepatocellular carcinoma ⁷⁴	11.44	TP53 MIR744 BRCA1
19	DNA damage response (only ATM dependent) ⁷⁴	11.36	TP53 KRAS HRAS ERBB2 BAX
20	Integrated cancer pathway ⁷⁴	11.21	TP53 BRCA1 BAX
21	Bladder cancer ⁷⁴	11.06	TP53 KRAS HRAS ERBB2
22	Extracellular vesicle-mediated signaling in recipient cells ⁷⁴	11.03	KRAS HRAS ERBB2
23	Pathways affected in adenoid cystic carcinoma ⁷⁴	10.81	TP53 HRAS ERBB2 BRCA1 ARID1A
24	TNF-alpha signaling pathway ⁷⁴ Show member pathways RAS GTPase cycle mutants ⁶⁶ Signaling by RAS GAP mutants ⁶⁶ Signaling by RAS GTPase mutants ⁶⁶	10.7	KRAS HRAS
25	Mammary gland development pathway - Involution (Stage 4 of 4) ⁷⁴	10.61	TP53 BAX

Sources

GO Terms for Ovary Adenocarcinoma

Cellular components related to Ovary Adenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	RISC complex	GO:0016442	9.8	MIR744 MIR30A MIR29C MIR196A1 MIR17 MIR152
2	extracellular vesicle	GO:1903561	9.02	MIR30A MIR29C MIR17 MIR152 MIR101-1

Biological processes related to Ovary Adenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	miRNA-mediated gene silencing	GO:0035195	10	MIR101-1 MIR152 MIR17 MIR196A1 MIR29C MIR30A
2	negative regulation of gene expression	GO:0010629	9.91	TP53 MIR29C MIR17 MIR101-1 HRAS
3	intrinsic apoptotic signaling pathway	GO:0097193	9.73	TP53 HRAS BAX
4	regulation of mitochondrial membrane permeability involved in apoptotic process	GO:1902108	9.54	TP53 BAX
5	neuron apoptotic process	GO:0051402	9.5	TP53 KRAS HRAS BAX
6	positive regulation of mitochondrial membrane permeability involved in apoptotic process	GO:1902110	9.4	MIR29C BAX
7	positive regulation of gene expression	GO:0010628	9.4	TP53 MIR17 MIR101-1 KRAS INHBA HRAS
8	negative regulation of metalloendopeptidase activity	GO:1904684	9.32	MIR29C MIR152

Molecular functions related to Ovary Adenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	mRNA 3'-UTR binding	GO:0003730	9.5	TP53 MIR30A MIR29C MIR17 MIR152 MIR101-1
2	mRNA base-pairing translational repressor activity	GO:1903231	9.1	MIR30A MIR29C MIR196A1 MIR17 MIR152 MIR101-1